AstraZeneka filed a claim with the Moscow Arbitration Court to protect the rights to a cancer drug to protect the rights to the drug “Tagrisso”. According to Irina Panarina, the general director of AstraZeneka in Russia, the company's rights could have been violated. The beginning of the trial is reported by RBC.
Tagrisso is an anticancer drug registered by AstraZeneka in Russia in 2017. The drug's patent is still valid, and Tagrisso's global sales bring the company 14.6 percent of its annual revenue – several billion dollars.
Related materials00: 02 – October 25 
Miraculous healing. A new material for rapid wound healing has been created in Russia. How does it work? 00:01 – September 8 
“The lack of vaccines is a shame” The acute phase of the pandemic could drag on for years. How can humanity defeat the coronavirus?
The Russian organization Axelpharm will be the defendant in the case. AstraZeneka believes that Axelpharm is going to release a generic version of its drug Tagrisso. To do this, the Russian company wants to obtain permission to release its drug from the Russian Ministry of Health. According to AstraZeneka, the Ministry of Health should not issue a permit before the patent expires.
The court hearing is scheduled for November 22.
Previously, Axelpharm has already become a defendant in patent law cases. Problems with the regulation of intellectual property rights in the pharmaceutical industry in Russia often lead to litigation.